Search by Drug Name or NDC
NDC 69097-0655-02 Ritonavir 100 mg/1 Details
Ritonavir 100 mg/1
Ritonavir is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Cipla USA Inc.. The primary component is RITONAVIR.
MedlinePlus Drug Summary
Ritonavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Ritonavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although ritonavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 69097-0655-02Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Ritonavir
Product Information
| NDC | 69097-0655 |
|---|---|
| Product ID | 69097-655_eeb20aab-f62a-4d80-92d1-2d6b3e2a5758 |
| Associated GPIs | |
| GCN Sequence Number | 066047 |
| GCN Sequence Number Description | ritonavir TABLET 100 MG ORAL |
| HIC3 | W5C |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITORS |
| GCN | 28224 |
| HICL Sequence Number | 010412 |
| HICL Sequence Number Description | RITONAVIR |
| Brand/Generic | Generic |
| Proprietary Name | Ritonavir |
| Proprietary Name Suffix | film coated |
| Non-Proprietary Name | ritonavir 100 mg |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 100 |
| Active Ingredient Units | mg/1 |
| Substance Name | RITONAVIR |
| Labeler Name | Cipla USA Inc. |
| Pharmaceutical Class | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A In |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA202573 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 69097-0655-02 (69097065502)
| NDC Package Code | 69097-655-02 |
|---|---|
| Billing NDC | 69097065502 |
| Package | 30 TABLET in 1 CONTAINER (69097-655-02) |
| Marketing Start Date | 2022-03-23 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 1.05096 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | RITONAVIR 100 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis